Edgar Filing: Visioli Christopher

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â Visioli Christopher

2. Date of Event Requiring Statement (Month/Day/Year)
03/21/2018

3. Issuer Name and Ticker or Trading Symbol
MEDICINES CO /DE [MDCO]

(Last)

(First)

(Middle)

C/O THE MEDICINES COMPANY,Â 8 SYLVAN WAY

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
Chief Financial Officer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

PARSIPPANY,Â NJÂ 07054

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	8,161	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right-to-buy)	Â ⁽¹⁾	02/18/2021	Common Stock	6,000	$ 17.45	D	Â
Stock Option (right-to-buy)	Â ⁽²⁾	02/24/2022	Common Stock	6,635	$ 22.04	D	Â
Stock Option (right-to-buy)	Â ⁽³⁾	03/01/2023	Common Stock	1,441	$ 31.49	D	Â
Stock Option (right-to-buy)	Â ⁽⁴⁾	03/01/2024	Common Stock	3,477	$ 30.55	D	Â
Stock Option (right-to-buy)	Â ⁽⁵⁾	03/01/2025	Common Stock	4,375	$ 28.77	D	Â
Stock Option (right-to-buy)	Â ⁽⁶⁾	03/01/2025	Common Stock	16,500	$ 28.77	D	Â
Stock Option (right-to-buy)	Â ⁽⁷⁾	03/01/2026	Common Stock	12,889	$ 33.04	D	Â
Stock Option (right-to-buy)	Â ⁽⁸⁾	03/01/2027	Common Stock	15,810	$ 52.7	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Visioli Christopher C/O THE MEDICINES COMPANY 8 SYLVAN WAY PARSIPPANY,Â NJÂ 07054	Â	Â	Â Chief Financial Officer	Â

Signatures

/s/ Stephen M. Rodin, Attorney-in-Fact for Christopher Visioli		04/02/2018
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Remainder of a grant of 20,000 stock options made to the reporting person on February 18, 2011. The remaining option vested in forty-eight equal monthly installments beginning March 18, 2011.
(2)	Remainder of a grant of 12,500 stock options made to the reporting person on February 24, 2012. The remaining option vested in forty-eight equal monthly installments beginning March 24, 2012.
(3)	Remainder of a grant of 3,843 stock options made to the reporting person on March 1, 2013. The remaining option vested in forty-eight equal monthly installments beginning April 1, 2013.
(4)	Remainder of a grant of 7,163 stock options made to the reporting person on March 1, 2014. The remaining option vested in forty-eight equal monthly installments beginning April 1, 2014.
(5)	Remainder of a grant of 5,000 stock options made to the reporting person on March 1, 2015. The option vests in equal monthly installments ending on April 1, 2019.
(6)	Remainder of a grant of 20,000 stock options made to the reporting person on March 1, 2015. The option vests in equal monthly installments ending on April 1, 2019.
(7)	Remainder of a grant of 14,889 stock options made to the reporting person on March 1, 2016. The option vests in equal monthly installments ending on April 1, 2020.
(8)	Grant made to the reporting person on March 1, 2017. The option vests in forty-eight equal installments ending April 1, 2021.
Â Remarks: ExhibitÂ List:Â ExhibitÂ 24.1Â -Â PowerÂ ofÂ Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.